| Followers | 48 |
| Posts | 23857 |
| Boards Moderated | 0 |
| Alias Born | 09/16/2012 |
Tuesday, May 19, 2026 8:02:02 AM
Do you really believe that one has nothing to do with the other? Looks like Canaccord was just the sacrificial lamb?
Settlement OverviewTotal Penalty: $80 million, which represented the largest fine ever imposed by FinCEN against a broker-dealer at the time.Financial Impact: Canaccord Genuity Group Inc. stated the actual resulting financial impact to the firm was approximately US$75.0 million (C$102.6 million), as a portion of the penalty was suspended pending satisfactory review of its suspicious activity reports.Regulatory Bodies: Settlements were simultaneously reached with the Financial Crimes Enforcement Network (FinCEN), the Securities and Exchange Commission (SEC), and FINRA.Key ViolationsFailure to Report: Canaccord failed to submit at least 160 Suspicious Activity Reports (SARs) regarding trading in dozens of over-the-counter (OTC) securities.Lax Internal Controls: Investigators found that Canaccord’s AML surveillance, customer due diligence procedures, and review processes were vastly under-resourced, causing compliance staff to be overwhelmed and under-trained.Market Abuse: The compliance gaps prevented the firm from identifying manipulative and suspicious trading, which hindered law enforcement's ability to combat financial misconduct and market abuse.Resolution & Company ResponseLeadership Changes: In response to the probes, Canaccord's board appointed new executive leadership and overhauled its compliance and oversight structures.Cantor Fitzgerald Acquisition: This major compliance settlement occurred while the investment bank was completing transactions to divest its U.S. wholesale market-making business, which had been previously agreed upon to be acquired by Cantor Fitzgerald.
Settlement OverviewTotal Penalty: $80 million, which represented the largest fine ever imposed by FinCEN against a broker-dealer at the time.Financial Impact: Canaccord Genuity Group Inc. stated the actual resulting financial impact to the firm was approximately US$75.0 million (C$102.6 million), as a portion of the penalty was suspended pending satisfactory review of its suspicious activity reports.Regulatory Bodies: Settlements were simultaneously reached with the Financial Crimes Enforcement Network (FinCEN), the Securities and Exchange Commission (SEC), and FINRA.Key ViolationsFailure to Report: Canaccord failed to submit at least 160 Suspicious Activity Reports (SARs) regarding trading in dozens of over-the-counter (OTC) securities.Lax Internal Controls: Investigators found that Canaccord’s AML surveillance, customer due diligence procedures, and review processes were vastly under-resourced, causing compliance staff to be overwhelmed and under-trained.Market Abuse: The compliance gaps prevented the firm from identifying manipulative and suspicious trading, which hindered law enforcement's ability to combat financial misconduct and market abuse.Resolution & Company ResponseLeadership Changes: In response to the probes, Canaccord's board appointed new executive leadership and overhauled its compliance and oversight structures.Cantor Fitzgerald Acquisition: This major compliance settlement occurred while the investment bank was completing transactions to divest its U.S. wholesale market-making business, which had been previously agreed upon to be acquired by Cantor Fitzgerald.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
